Development of detecting circulating renal cancer cells that have Death Receptor 5 as a surface marker

开发出检测以死亡受体 5 作为表面标志物的循环肾癌细胞

• 批准号: 23791760
• 负责人: HIRAMA Hiromi
• 金额: $ 2.66万
• 依托单位: Kagawa University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23791760/
• 关键词: 末梢血循環腫瘍細胞; 腎癌; Death Receptor 5; 末梢循環癌細胞; 腎癌患者; 転移性癌患者; 抹消血; DR－５; ＤＲ－５

This research was planned with the objective of detecting cancer cells at extremely low volumes circulating in the blood of renal cell carcinoma patients (circulating tumor cells (CTC) in peripheral blood), using fluorescence-labeled antibodies for DR-5, a surface marker of renal cancer cells.In a preliminary experiment, it was possible to count renal cancer cells as CTC. However, in the peripheral blood of localized and metastatic renal cell carcinoma patients (respectively 15 and 4 patients), the positive detection rate for DR-5 was low, and CTC detection was difficult. Moreover, CTC measurement using the blood in the renal veins that first flowed from the kidneys was performed for 13 patients, but there was significant contamination given that this was subsequent to renal excision, and it was found to be unsuitable for CTC measurement.

本研究的目的是使用肾癌细胞表面标记物DR-5的荧光标记抗体，检测肾癌患者血液中极少量的癌细胞（外周血中的循环肿瘤细胞（CTC）），初步实验中，可以将肾癌细胞计数为CTC。但在局限性和转移性肾细胞癌患者外周血中（分别为15例和4例），DR-5的阳性检出率较低，CTC检测困难。此外，对13名患者进行了使用首先从肾脏流出的肾静脉中的血液的CTC测量，但是由于这是在肾切除之后，因此存在显著污染，并且发现其不适合CTC测量。